Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP) Gallagher, E. J., Moore, H., Lacouture, M. E., Dent, S., Farooki, A., Goncalves, M. D., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., Spring, L., Berman, B., Decker, M., Hortobagyi, G. N., Kaffenberger, B., Kwong, B. Y., Pluard, T. J., Rao, R. D., Schwartzberg, L. S., Broder, M. S. LIPPINCOTT WILLIAMS & WILKINS. 2022: 422

View details for Web of Science ID 000891944700418